summit clinical trial tirzepatide JACC - #ACC25: A recent #JACC publication on the evaluates in patients with #HFpEF, with secondary analyses focusing on (1) cardiac structure and (2) #CKD. https://bit.ly/3EdDCQK SURMOUNT-1 Trial - Cardionerds Twitter

In summary, this study revealed that dysfunction of cellular transport of cytoplasmic FA to mitochondria plays a critical role in UA-induced cardiomyocyte injury and thereby promotes LVR development and identified CPT1B as the key factor influenced by UA

Linearity of D-Carnitine

To assess the nanotoxicity in a complex way, all-inclusive hemocompatibility testing, which includes assessment of hematocrit, hemostasis, nano-cell interactions, immunotoxic effects, etc., is recommended [448]

Many practitioners split this into twice-weekly injections for more stable blood levels

"Your firm became aware of the event on June 20, 2024, and FDA received the MDR, 1220908202500947, for the corresponding incident on March 10, 2025, which is beyond the 30calendar day timeframe." FDA issued warning letters to three drug manufacturers, including the Canadian over-the-counter drugmaker Sante Manufacturing, for failing to adhere to CGMP requirements